Author: Ravi Shankar

Unusual Machines (NYSE American: UMAC) and a leading U.S. Investment Fund make a strategic investment of $10M, each investing $5M into Draganfly, in support of the Company’s growing position in the U.S. defense ecosystem while also gaining access to strategic opportunities in international markets uniquely served by Draganfly.

TAMPA, Fla., Sept. 28, 2026 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an industry-leading developer of drone solutions, systems and technologies, announces a US$10 million strategic investment by Unusual Machines, Inc. (NYSE American: UMAC) and a leading U.S. Investment Fund, each investing $5M (the “Investment”).

This strategic investment comes during a period of accelerating commercial and defense activity for Draganfly across both the United States and Canada, including significant recent procurement milestones with the Canadian Armed Forces and continued important expansion of the Company’s U.S. defense operations.

Draganfly intends to use the net proceeds to accelerate the development of advanced strategic capabilities and to fund general working capital in meeting demand for its products in the rapidly maturing U.S. and international markets.

“We are seeing the convergence of customer adoption, government procurement, domestic manufacturing, defense autonomy and strategic industry participation,” said Cameron Chell, CEO and Chairman of Draganfly. “This strategic investment from Unusual Machines and a leading U.S. Investment Fund is about positioning, not size. It is about aligning capabilities that can best serve the industries’ requirements at scale domestically and abroad.”

“America and its allies are entering a period in which the ability to manufacture drones, components and autonomous systems at scale is becoming a strategic capability,” said Dr. Allan Evans, CEO of Unusual Machines. “This investment into Draganfly allows us to support their production growth and deepen our supplier relationships.”

The Investment is priced at-market based on the closing price of the Company’s common shares on Friday, September 25, 2026^, and represents an important step in the maturation of the US and international drone supply chain and ecosystem.

The Investment is a registered direct offering to purchase 1,869,159 common shares of the Company at a price of US$5.35, for gross proceeds of approximately US$10 million, before deducting placement agent discounts and offering expenses.

Jett Capital Advisors, LLC and Northland Capital Markets are acting as joint-lead placement agents in the offering.

The Investment is expected to close on or about September 29, 2026, subject to the satisfaction of customary closing conditions, including receipt of all necessary regulatory approvals, including approval of the Canadian Securities Exchange and notification to the Nasdaq Stock Market.

The Investment is being made pursuant to an effective shelf registration statement on Form F-10, as amended (File No. 333-290823), previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on February 25, 2026, and the Company’s Canadian short form base shelf prospectus dated October 24, 2025 (the “Base Shelf Prospectus”). Draganfly will offer and sell the securities in the United States only. No securities will be offered or sold to Canadian purchasers.

A prospectus supplement and accompanying Base Shelf Prospectus relating to the Investment and describing the terms thereof will be filed with the applicable securities commissions in Canada and with the SEC in the United States and will be available for free by visiting the Company’s profiles on the SEDAR+ website maintained by the Canadian Securities Administrators at www.sedarplus.ca or the SEC’s website at www.sec.gov, as applicable. Copies of the prospectus supplement and accompanying Base Shelf Prospectus relating to the Investment may be obtained, when available, by contacting Jett Capital Advisors, LLC, at 712 Fifth Ave, 11th Floor, New York, NY 10019, Attention: General Inquiries, or by telephone at +1-212-616-0430 or by email at info@jettcapital.com, or Northland Securities, Inc., at 150 South Fifth Street, Suite 3300, Minneapolis, MN 55402, Attention: Valencia Day, or by telephone at +1-612-851-4917, or by email at vday@northlandcapitalmarkets.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Draganfly

Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8) is a leader in cutting-edge drone solutions and software that are transforming industries and serving stakeholders globally. Recognized for innovation and excellence for over 27 years, Draganfly delivers award-winning technology to the public safety, civil, military, agriculture, industrial inspection, security, mapping, and surveying markets. The Company is driven by passion, ingenuity, and a mission to provide efficient solutions and first-class services to customers worldwide, saving time, money, and lives.

For more information, visit www.draganfly.com.

For investor details, visit:
NASDAQ (DPRO)
CSE (DPRO)
FSE (3U8)

Media Contact

Erika Racicot
Email: media@draganfly.com

Company Contact

Cameron Chell
Chief Executive Officer
(306) 955-9907
Email: info@draganfly.com

Forward-Looking Statements

This release contains certain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Forward-looking statements in this news release include, but are not limited to: statements regarding the timing, size and expected gross proceeds of the Investment; the satisfaction of customary closing conditions related to the Investment and sale of securities; the intended use of proceeds; Draganfly’s ability to complete the Investment; expansion of U.S. and North American manufacturing, development and commercialization of drone, counter-UAS and autonomous technologies, potential future orders under existing contracts, potential strategic relationships, acquisitions and partnerships, and the Company’s anticipated opportunities within U.S., Canadian and allied defense markets. Forward-looking statements are based on the current expectations of management, are subject to numerous assumptions, risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results to differ materially from those expressed or implied. Actual future events may differ from the anticipated events expressed in such forward-looking statements. Draganfly believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These forward looking statements speak only as of the date made, and Draganfly is under no obligation and disavows any intention to update publicly or revise such statements as a result of any new information, future event, circumstances or otherwise, unless required by applicable securities laws. Investors are cautioned not to unduly rely on these forward-looking statements and are encouraged to read the Investment documents, as well as Draganfly’s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov/edgar.

Unusual Machines (NYSE American: UMAC) and a leading U.S. Investment Fund make a strategic investment of $10M, each investing $5M into Draganfly, in support of the Company’s growing position in the U.S. defense ecosystem while also gaining access to strategic opportunities in international markets uniquely served by Draganfly.

TAMPA, Fla., Sept. 28, 2026 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an industry-leading developer of drone solutions, systems and technologies, announces a US$10 million strategic investment by Unusual Machines, Inc. (NYSE American: UMAC) and a leading U.S. Investment Fund, each investing $5M (the “Investment”).

This strategic investment comes during a period of accelerating commercial and defense activity for Draganfly across both the United States and Canada, including significant recent procurement milestones with the Canadian Armed Forces and continued important expansion of the Company’s U.S. defense operations.

Draganfly intends to use the net proceeds to accelerate the development of advanced strategic capabilities and to fund general working capital in meeting demand for its products in the rapidly maturing U.S. and international markets.

“We are seeing the convergence of customer adoption, government procurement, domestic manufacturing, defense autonomy and strategic industry participation,” said Cameron Chell, CEO and Chairman of Draganfly. “This strategic investment from Unusual Machines and a leading U.S. Investment Fund is about positioning, not size. It is about aligning capabilities that can best serve the industries’ requirements at scale domestically and abroad.”

“America and its allies are entering a period in which the ability to manufacture drones, components and autonomous systems at scale is becoming a strategic capability,” said Dr. Allan Evans, CEO of Unusual Machines. “This investment into Draganfly allows us to support their production growth and deepen our supplier relationships.”

The Investment is priced at-market based on the closing price of the Company’s common shares on Friday, September 25, 2026^, and represents an important step in the maturation of the US and international drone supply chain and ecosystem.

The Investment is a registered direct offering to purchase 1,869,159 common shares of the Company at a price of US$5.35, for gross proceeds of approximately US$10 million, before deducting placement agent discounts and offering expenses.

Jett Capital Advisors, LLC and Northland Capital Markets are acting as joint-lead placement agents in the offering.

The Investment is expected to close on or about September 29, 2026, subject to the satisfaction of customary closing conditions, including receipt of all necessary regulatory approvals, including approval of the Canadian Securities Exchange and notification to the Nasdaq Stock Market.

The Investment is being made pursuant to an effective shelf registration statement on Form F-10, as amended (File No. 333-290823), previously filed with and subsequently declared effective by the U.S. Securities and Exchange Commission (“SEC”) on February 25, 2026, and the Company’s Canadian short form base shelf prospectus dated October 24, 2025 (the “Base Shelf Prospectus”). Draganfly will offer and sell the securities in the United States only. No securities will be offered or sold to Canadian purchasers.

A prospectus supplement and accompanying Base Shelf Prospectus relating to the Investment and describing the terms thereof will be filed with the applicable securities commissions in Canada and with the SEC in the United States and will be available for free by visiting the Company’s profiles on the SEDAR+ website maintained by the Canadian Securities Administrators at www.sedarplus.ca or the SEC’s website at www.sec.gov, as applicable. Copies of the prospectus supplement and accompanying Base Shelf Prospectus relating to the Investment may be obtained, when available, by contacting Jett Capital Advisors, LLC, at 712 Fifth Ave, 11th Floor, New York, NY 10019, Attention: General Inquiries, or by telephone at +1-212-616-0430 or by email at info@jettcapital.com, or Northland Securities, Inc., at 150 South Fifth Street, Suite 3300, Minneapolis, MN 55402, Attention: Valencia Day, or by telephone at +1-612-851-4917, or by email at vday@northlandcapitalmarkets.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Draganfly

Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8) is a leader in cutting-edge drone solutions and software that are transforming industries and serving stakeholders globally. Recognized for innovation and excellence for over 27 years, Draganfly delivers award-winning technology to the public safety, civil, military, agriculture, industrial inspection, security, mapping, and surveying markets. The Company is driven by passion, ingenuity, and a mission to provide efficient solutions and first-class services to customers worldwide, saving time, money, and lives.

For more information, visit www.draganfly.com.

For investor details, visit:
NASDAQ (DPRO)
CSE (DPRO)
FSE (3U8)

Media Contact

Erika Racicot
Email: media@draganfly.com

Company Contact

Cameron Chell
Chief Executive Officer
(306) 955-9907
Email: info@draganfly.com

Forward-Looking Statements

This release contains certain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Forward-looking statements in this news release include, but are not limited to: statements regarding the timing, size and expected gross proceeds of the Investment; the satisfaction of customary closing conditions related to the Investment and sale of securities; the intended use of proceeds; Draganfly’s ability to complete the Investment; expansion of U.S. and North American manufacturing, development and commercialization of drone, counter-UAS and autonomous technologies, potential future orders under existing contracts, potential strategic relationships, acquisitions and partnerships, and the Company’s anticipated opportunities within U.S., Canadian and allied defense markets. Forward-looking statements are based on the current expectations of management, are subject to numerous assumptions, risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results to differ materially from those expressed or implied. Actual future events may differ from the anticipated events expressed in such forward-looking statements. Draganfly believes that expectations represented by forward-looking statements are reasonable, yet there can be no assurance that such expectations will prove to be correct. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These forward looking statements speak only as of the date made, and Draganfly is under no obligation and disavows any intention to update publicly or revise such statements as a result of any new information, future event, circumstances or otherwise, unless required by applicable securities laws. Investors are cautioned not to unduly rely on these forward-looking statements and are encouraged to read the Investment documents, as well as Draganfly’s continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov/edgar.

TORONTO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) announces that the Toronto Stock Exchange (the “TSX”) has accepted a notice filed by Fairfax of its intention to commence a Normal Course Issuer Bid (“NCIB”) through the facilities of the TSX (or other alternative Canadian trading systems) for its Subordinate Voting Shares and Cumulative 5-Year Rate Reset Preferred Shares, Series K (the “Series K Shares”) (TSX: FFH.PR.K). Purchases will be made in accordance with the rules and policies of the TSX. Subordinate Voting Shares purchased will be either cancelled or reserved for share-based payment awards and Series K Shares purchased will be cancelled.

As stated in the notice, Fairfax’s board of directors has approved the purchase on the TSX, during the period commencing September 30, 2026 and ending September 29, 2027, of Subordinate Voting Shares and Series K Shares up to the following limits:

									Limit on Purchases
			Securities Outstanding1		Public Float		Average Daily Trading Volume		Total Limit2		Daily Limit3
Subordinate Voting Shares			20,823,876		20,253,151		60,551		2,025,315		15,137
Series K Shares			9,500,000		9,500,000		8,907		950,000		2,226
Notes
1.	As of September 16, 2026.
2.	Represents approximately 10% of the public float in respect of each of the Subordinate Voting Shares and the Series K Shares.
3.	Represents the maximum number of shares of that class or series that may be purchased over the TSX during the course of one trading day. This amount is equal to the greater of (i) 25% of the average daily trading volume on the TSX calculated in accordance with the rules of the TSX, and (ii) 1,000 shares. This limitation does not apply to purchases made pursuant to block purchase exemptions.

Fairfax is making this NCIB because it believes that in appropriate circumstances its Subordinate Voting Shares and Series K Shares represent an attractive investment opportunity and that, with respect to the Subordinate Voting Shares, purchases under the bid will enhance the value of the Subordinate Voting Shares held by the remaining shareholders.

Pursuant to its existing normal course issuer bid, Fairfax sought and received approval from the TSX to purchase up to 2,187,316 Subordinate Voting Shares, 1,042,010 Cumulative 5-Year Rate Reset Preferred Shares, Series I, 157,989 Cumulative 5-Year Rate Reset Preferred Shares, Series J and 950,000 Series K Shares. Under its existing normal course issuer bid, Fairfax has purchased 1,593,566 of its Subordinate Voting Shares, which included Subordinate Voting Shares reserved for share-based payment awards, through open market purchases on the TSX and other alternative Canadian trading systems during the last twelve months at a volume weighted average price per share of Cdn.$2,280.87. Fairfax has not purchased any preferred shares under its existing normal course issuer bid.

Fairfax also announces that it has entered into an automatic share purchase plan (the “ASPP”) with a designated broker to allow for the purchase of its Subordinate Voting Shares and Series K Shares under the NCIB at times when Fairfax normally would not be active in the market due to applicable regulatory restrictions or internal trading black-out periods. Before the commencement of any particular internal trading black-out period, Fairfax may, but is not required to, instruct its designated broker to make purchases of Subordinate Voting Shares and/or Series K Shares under the NCIB during the ensuing black-out period in accordance with the terms of the ASPP. Such purchases will be determined by the broker in its sole discretion based on parameters established by Fairfax prior to commencement of the applicable black-out period in accordance with the terms of the ASPP and applicable TSX rules. Outside of these black-out periods, Subordinate Voting Shares and Series K Shares will be purchasable by Fairfax at its discretion under its NCIB.

The ASPP is effective as of September 30, 2026 and will terminate on the earliest of the date on which: (a) the maximum annual purchase limit in respect of the Subordinate Voting Shares and the Series K Shares under the NCIB has been reached; (b) the NCIB expires; or (c) Fairfax terminates the ASPP in accordance with its terms. The ASPP constitutes an “automatic securities purchase plan” under applicable Canadian securities laws.

Fairfax is a holding company which, through its subsidiaries, is primarily engaged in property and casualty insurance and reinsurance and the associated investment management.

For further information contact:

John Varnell, Vice President, Corporate Development at (416) 367-4941

TORONTO, Sept. 28, 2026 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) announces that the Toronto Stock Exchange (the “TSX”) has accepted a notice filed by Fairfax of its intention to commence a Normal Course Issuer Bid (“NCIB”) through the facilities of the TSX (or other alternative Canadian trading systems) for its Subordinate Voting Shares and Cumulative 5-Year Rate Reset Preferred Shares, Series K (the “Series K Shares”) (TSX: FFH.PR.K). Purchases will be made in accordance with the rules and policies of the TSX. Subordinate Voting Shares purchased will be either cancelled or reserved for share-based payment awards and Series K Shares purchased will be cancelled.

As stated in the notice, Fairfax’s board of directors has approved the purchase on the TSX, during the period commencing September 30, 2026 and ending September 29, 2027, of Subordinate Voting Shares and Series K Shares up to the following limits:

									Limit on Purchases
			Securities Outstanding1		Public Float		Average Daily Trading Volume		Total Limit2		Daily Limit3
Subordinate Voting Shares			20,823,876		20,253,151		60,551		2,025,315		15,137
Series K Shares			9,500,000		9,500,000		8,907		950,000		2,226
Notes
1.	As of September 16, 2026.
2.	Represents approximately 10% of the public float in respect of each of the Subordinate Voting Shares and the Series K Shares.
3.	Represents the maximum number of shares of that class or series that may be purchased over the TSX during the course of one trading day. This amount is equal to the greater of (i) 25% of the average daily trading volume on the TSX calculated in accordance with the rules of the TSX, and (ii) 1,000 shares. This limitation does not apply to purchases made pursuant to block purchase exemptions.

Fairfax is making this NCIB because it believes that in appropriate circumstances its Subordinate Voting Shares and Series K Shares represent an attractive investment opportunity and that, with respect to the Subordinate Voting Shares, purchases under the bid will enhance the value of the Subordinate Voting Shares held by the remaining shareholders.

Pursuant to its existing normal course issuer bid, Fairfax sought and received approval from the TSX to purchase up to 2,187,316 Subordinate Voting Shares, 1,042,010 Cumulative 5-Year Rate Reset Preferred Shares, Series I, 157,989 Cumulative 5-Year Rate Reset Preferred Shares, Series J and 950,000 Series K Shares. Under its existing normal course issuer bid, Fairfax has purchased 1,593,566 of its Subordinate Voting Shares, which included Subordinate Voting Shares reserved for share-based payment awards, through open market purchases on the TSX and other alternative Canadian trading systems during the last twelve months at a volume weighted average price per share of Cdn.$2,280.87. Fairfax has not purchased any preferred shares under its existing normal course issuer bid.

Fairfax also announces that it has entered into an automatic share purchase plan (the “ASPP”) with a designated broker to allow for the purchase of its Subordinate Voting Shares and Series K Shares under the NCIB at times when Fairfax normally would not be active in the market due to applicable regulatory restrictions or internal trading black-out periods. Before the commencement of any particular internal trading black-out period, Fairfax may, but is not required to, instruct its designated broker to make purchases of Subordinate Voting Shares and/or Series K Shares under the NCIB during the ensuing black-out period in accordance with the terms of the ASPP. Such purchases will be determined by the broker in its sole discretion based on parameters established by Fairfax prior to commencement of the applicable black-out period in accordance with the terms of the ASPP and applicable TSX rules. Outside of these black-out periods, Subordinate Voting Shares and Series K Shares will be purchasable by Fairfax at its discretion under its NCIB.

The ASPP is effective as of September 30, 2026 and will terminate on the earliest of the date on which: (a) the maximum annual purchase limit in respect of the Subordinate Voting Shares and the Series K Shares under the NCIB has been reached; (b) the NCIB expires; or (c) Fairfax terminates the ASPP in accordance with its terms. The ASPP constitutes an “automatic securities purchase plan” under applicable Canadian securities laws.

Fairfax is a holding company which, through its subsidiaries, is primarily engaged in property and casualty insurance and reinsurance and the associated investment management.

For further information contact:

John Varnell, Vice President, Corporate Development at (416) 367-4941

Potential Follow-On Orders Could Bring Total Orders to Approximately US$14.1 Million; Majority of the Initial Order Expected to Be Delivered by the End of 2028

Rehovot, Israel, Sept. 28, 2026 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global leader in edge computing, AI, and video intelligence solutions for defense applications, today announced that it has received an order valued at US$10 million for the development and supply of advanced video systems for multiple next-generation manned airborne platforms.

The order was received pursuant to a multi-year project being carried out by Magam Safety Ltd. (“Magam”) and Maris-Tech who will collaborate jointly in order to supply the advanced Video Systems for Next-Generation Airborne Defense Platforms.

Founded in 1934, Magam designs, manufactures and markets protective gear and rescue and survivability equipment for the aerospace, defense and health and life sciences sectors, and supplies products to the Israel Defense Forces. Its interdisciplinary team of textile, rubber and personal-protection experts, engineers and product designers deliver both off-the-shelf and tailored solutions, including fuel tanks, parachutes, life jackets, life rafts and anti-mine protectors.

The US$10 million order is part of a multi-year project that includes additional purchase options. If such options are exercised, Maris-Tech expects to receive additional orders that would bring the total value of orders received by Maris-Tech under the project to approximately US$14.1 million. The additional orders are subject to the exercise of such options.

Under the project, Maris-Tech will modify and upgrade some of its existing products and develop and supply advanced video systems for integration across multiple next-generation manned airborne platforms. The systems will be based on the Company’s field-proven Jupiter product line of video, AI edge-computing and streaming platforms, as well as the Company’s Opal high-end, ruggedized advanced video recording and NAS (Network Attached Storage) server software. The systems are designed to support the video requirements of the platforms in demanding airborne operating environments.

Maris-Tech expects to complete deliveries representing approximately US$7.1 million of the order value by the end of 2028.

Israel Bar, Chief Executive Officer of Maris-Tech, said: “This project reflects the continued application of our video capabilities in airborne environments. Working together with Magam we will support the development and supply of video systems across multiple next-generation platforms over the coming years.”

Amit Tesler, Chairman of Magam, said: “Magam has supplied the defense market for more than nine decades. Our cooperation with Maris-Tech on this project brings its video capabilities to the next-generation airborne platforms covered by the project, and we look forward to working together over the course of the project.”

About Maris-Tech Ltd.

Maris-Tech delivers AI-powered edge video solutions for mission-critical defense and security operations, enabling real-time situational awareness, intelligence gathering, and surveillance in bandwidth- and latency-constrained environments. Trusted by leading security organizations, Maris-Tech platforms are deployed across UAVs, UGVs, armored vehicles, and dismounted soldier systems, supporting missions that require ultra-low-latency video processing and onboard AI analytics. From intelligence collection in extreme conditions to AI-driven surveillance and terrain dominance, Maris-Tech masters the AI video pipeline at the edge through best-in-class SWaP-optimized, ruggedized computing solutions.

For more information, visit https://www.maris-tech.com/

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect”,” “may”, “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it is discussing the anticipated scope, value, timing and delivery of the order, the potential for additional orders if additional purchase options are exercised, anticipated deliveries by the end of 2028, the Company’s cooperation with Magam, the development, modification, integration and supply of the Company’s products, and the expected capabilities, performance and benefits of the Company’s products and systems in demanding airborne operating environments. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the performance, amendment, suspension or termination of the applicable project; its ability to successfully market its products and services, including in the United States; the acceptance of its products and services by customers; its continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; its ability to successfully develop new products and services; its success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; the actions, decisions, performance and approvals of Magam, the end customer and other third parties, including the exercise of options and placement of additional orders; its ability to comply with applicable regulations; and the other risks and uncertainties described in the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on May 15, 2026, and its other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations:

Nir Bussy, CFO
Tel: +972-72-2424022
Nir@maris-tech.com

Potential Follow-On Orders Could Bring Total Orders to Approximately US$14.1 Million; Majority of the Initial Order Expected to Be Delivered by the End of 2028

Rehovot, Israel, Sept. 28, 2026 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global leader in edge computing, AI, and video intelligence solutions for defense applications, today announced that it has received an order valued at US$10 million for the development and supply of advanced video systems for multiple next-generation manned airborne platforms.

The order was received pursuant to a multi-year project being carried out by Magam Safety Ltd. (“Magam”) and Maris-Tech who will collaborate jointly in order to supply the advanced Video Systems for Next-Generation Airborne Defense Platforms.

Founded in 1934, Magam designs, manufactures and markets protective gear and rescue and survivability equipment for the aerospace, defense and health and life sciences sectors, and supplies products to the Israel Defense Forces. Its interdisciplinary team of textile, rubber and personal-protection experts, engineers and product designers deliver both off-the-shelf and tailored solutions, including fuel tanks, parachutes, life jackets, life rafts and anti-mine protectors.

The US$10 million order is part of a multi-year project that includes additional purchase options. If such options are exercised, Maris-Tech expects to receive additional orders that would bring the total value of orders received by Maris-Tech under the project to approximately US$14.1 million. The additional orders are subject to the exercise of such options.

Under the project, Maris-Tech will modify and upgrade some of its existing products and develop and supply advanced video systems for integration across multiple next-generation manned airborne platforms. The systems will be based on the Company’s field-proven Jupiter product line of video, AI edge-computing and streaming platforms, as well as the Company’s Opal high-end, ruggedized advanced video recording and NAS (Network Attached Storage) server software. The systems are designed to support the video requirements of the platforms in demanding airborne operating environments.

Maris-Tech expects to complete deliveries representing approximately US$7.1 million of the order value by the end of 2028.

Israel Bar, Chief Executive Officer of Maris-Tech, said: “This project reflects the continued application of our video capabilities in airborne environments. Working together with Magam we will support the development and supply of video systems across multiple next-generation platforms over the coming years.”

Amit Tesler, Chairman of Magam, said: “Magam has supplied the defense market for more than nine decades. Our cooperation with Maris-Tech on this project brings its video capabilities to the next-generation airborne platforms covered by the project, and we look forward to working together over the course of the project.”

About Maris-Tech Ltd.

Maris-Tech delivers AI-powered edge video solutions for mission-critical defense and security operations, enabling real-time situational awareness, intelligence gathering, and surveillance in bandwidth- and latency-constrained environments. Trusted by leading security organizations, Maris-Tech platforms are deployed across UAVs, UGVs, armored vehicles, and dismounted soldier systems, supporting missions that require ultra-low-latency video processing and onboard AI analytics. From intelligence collection in extreme conditions to AI-driven surveillance and terrain dominance, Maris-Tech masters the AI video pipeline at the edge through best-in-class SWaP-optimized, ruggedized computing solutions.

For more information, visit https://www.maris-tech.com/

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect”,” “may”, “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it is discussing the anticipated scope, value, timing and delivery of the order, the potential for additional orders if additional purchase options are exercised, anticipated deliveries by the end of 2028, the Company’s cooperation with Magam, the development, modification, integration and supply of the Company’s products, and the expected capabilities, performance and benefits of the Company’s products and systems in demanding airborne operating environments. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: the performance, amendment, suspension or termination of the applicable project; its ability to successfully market its products and services, including in the United States; the acceptance of its products and services by customers; its continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; its ability to successfully develop new products and services; its success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; the actions, decisions, performance and approvals of Magam, the end customer and other third parties, including the exercise of options and placement of additional orders; its ability to comply with applicable regulations; and the other risks and uncertainties described in the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on May 15, 2026, and its other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations:

Nir Bussy, CFO
Tel: +972-72-2424022
Nir@maris-tech.com

Closing expected mid-October 2026

DENVER, Sept. 28, 2026 (GLOBE NEWSWIRE) — Intermap Technologies, a global leader in geospatial intelligence powered by proprietary 3D data and AI-driven analytics, today announced that shareholders (“PCI Shareholders”) of PCI Geomatics Group Inc. (“PCI,” aka. “CATALYST”) have approved Intermap’s previously announced acquisition of the remaining PCI shares. The acquisition includes all of the issued and outstanding shares in the capital of PCI not already owned by Intermap and will be completed by way of an arrangement under the Canada Business Corporations Act (the “Arrangement”).

On September 25, 2026, PCI held a special shareholder meeting in person and virtually, via live webcast (the “Meeting”), with PCI Shareholders voting on a special resolution in connection with the proposed Arrangement (the “Arrangement Resolution”). The Arrangement Resolution was approved by: (i) 99.99% of the votes cast by PCI Shareholders present in person or by proxy at the Meeting, voting as a single class; 99.99% of the votes cast by holders of common shares in the capital of PCI present in person or by proxy at the Meeting, excluding votes cast by certain officers and/or directors of PCI; 100% of the votes cast by holders of Series B first preferred shares in the capital of PCI present in person or by proxy at the Meeting; and 100% of the votes cast by holders of special shares in the capital of PCI present in person or by proxy at the Meeting.

“We are pleased to have received the support of PCI Shareholders and to reach this important milestone,” said Patrick Blott, Chairman and CEO of Intermap. “We look forward to completing the transaction and bringing Intermap and PCI together as one company, combining our proprietary 3D data, geospatial intelligence and advanced imagery processing capabilities to create a stronger platform for growth.”

The Arrangement is subject to the approval of the Ontario Superior Court of Justice (Commercial List) (the “Court”). The anticipated hearing date for the application for the final order of the Court (the “Final Order”) is September 28, 2026. Subject to obtaining the Final Order, and the satisfaction or waiver of the conditions to implementing the Arrangement as set out in the arrangement agreement dated July 28, 2026 among Intermap, PCI and Grenadier Investments Limited, the Arrangement is expected to be completed mid-October, 2026.

Intermap Reader Advisory 
Certain information provided in this news release, including reference to the timing, completion and expected benefits of the Arrangement and the timing of receipt of the Final Order constitutes forward-looking statements. The words “anticipate”, “expect”, “propose”, “will”, “look forward” and similar expressions are intended to identify such forward-looking statements. Although Intermap believes that these statements are based on information and assumptions which are current, reasonable and complete, these statements are necessarily subject to a variety of known and unknown risks and uncertainties. Intermap’s forward-looking statements are subject to risks and uncertainties pertaining to, among other things, cash available to fund operations, availability of capital, revenue fluctuations, nature of government contracts, economic conditions, loss of key customers, retention and availability of executive talent, competing technologies, common share price volatility, loss of proprietary information, software functionality, internet and system infrastructure functionality, information technology security, breakdown of strategic alliances, and international and political considerations, as well as those risks and uncertainties discussed in Intermap’s Annual Information Form and other securities filings. In addition, completion of the Arrangement is subject to receipt of court approvals, together with the satisfaction or waiver of certain conditions precedent to the Arrangement which are outside of the control of Intermap. While the Company makes these forward-looking statements in good faith, should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary significantly from those expected. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements, including the Arrangement, will transpire or occur, or if any of them do so, what benefits that the Company will derive therefrom. All subsequent forward-looking statements, whether written or oral, attributable to Intermap or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements made herein, whether as a result of new information, future events or otherwise, except as may be required by applicable securities law.

About Intermap Technologies 
Intermap Technologies is a global leader in geospatial intelligence powered by proprietary 3D data and AI-driven analytics. The Company delivers actionable intelligence to government and commercial customers through a portfolio of applications, platforms and solutions that support risk management, infrastructure planning, operational readiness and mission-critical decision-making. Intermap’s proprietary 3D data foundation spans more than 300 million square kilometers across over 150 countries and powers intelligence solutions for government, insurance, aviation, telecommunications, transportation, renewable energy, agriculture, natural resources and space markets. Through advanced analytics, automated processing and enterprise-scale data delivery, Intermap helps organizations transform complex geospatial information into decision-ready intelligence. 

About CATALYST (PCI)
PCI (DBA CATALYST) is a world-leading developer of software and systems for remote sensing, imagery processing, and photogrammetry. With 45 years of experience in the geospatial industry, CATALYST is recognized globally for its excellence in providing software for accurately and rapidly processing satellite and aerial imagery, with more than 30,000 licenses in over 150 countries worldwide.

For more information, please visit www.intermap.com or contact:
Jennifer Bakken
Executive Vice President and CFO
CFO@intermap.com
+1 (303) 708-0955

Sean Peasgood
Investor Relations
Sean@SophicCapital.com
+1 (647) 260-9266

Closing expected mid-October 2026

DENVER, Sept. 28, 2026 (GLOBE NEWSWIRE) — Intermap Technologies, a global leader in geospatial intelligence powered by proprietary 3D data and AI-driven analytics, today announced that shareholders (“PCI Shareholders”) of PCI Geomatics Group Inc. (“PCI,” aka. “CATALYST”) have approved Intermap’s previously announced acquisition of the remaining PCI shares. The acquisition includes all of the issued and outstanding shares in the capital of PCI not already owned by Intermap and will be completed by way of an arrangement under the Canada Business Corporations Act (the “Arrangement”).

On September 25, 2026, PCI held a special shareholder meeting in person and virtually, via live webcast (the “Meeting”), with PCI Shareholders voting on a special resolution in connection with the proposed Arrangement (the “Arrangement Resolution”). The Arrangement Resolution was approved by: (i) 99.99% of the votes cast by PCI Shareholders present in person or by proxy at the Meeting, voting as a single class; 99.99% of the votes cast by holders of common shares in the capital of PCI present in person or by proxy at the Meeting, excluding votes cast by certain officers and/or directors of PCI; 100% of the votes cast by holders of Series B first preferred shares in the capital of PCI present in person or by proxy at the Meeting; and 100% of the votes cast by holders of special shares in the capital of PCI present in person or by proxy at the Meeting.

“We are pleased to have received the support of PCI Shareholders and to reach this important milestone,” said Patrick Blott, Chairman and CEO of Intermap. “We look forward to completing the transaction and bringing Intermap and PCI together as one company, combining our proprietary 3D data, geospatial intelligence and advanced imagery processing capabilities to create a stronger platform for growth.”

The Arrangement is subject to the approval of the Ontario Superior Court of Justice (Commercial List) (the “Court”). The anticipated hearing date for the application for the final order of the Court (the “Final Order”) is September 28, 2026. Subject to obtaining the Final Order, and the satisfaction or waiver of the conditions to implementing the Arrangement as set out in the arrangement agreement dated July 28, 2026 among Intermap, PCI and Grenadier Investments Limited, the Arrangement is expected to be completed mid-October, 2026.

Intermap Reader Advisory 
Certain information provided in this news release, including reference to the timing, completion and expected benefits of the Arrangement and the timing of receipt of the Final Order constitutes forward-looking statements. The words “anticipate”, “expect”, “propose”, “will”, “look forward” and similar expressions are intended to identify such forward-looking statements. Although Intermap believes that these statements are based on information and assumptions which are current, reasonable and complete, these statements are necessarily subject to a variety of known and unknown risks and uncertainties. Intermap’s forward-looking statements are subject to risks and uncertainties pertaining to, among other things, cash available to fund operations, availability of capital, revenue fluctuations, nature of government contracts, economic conditions, loss of key customers, retention and availability of executive talent, competing technologies, common share price volatility, loss of proprietary information, software functionality, internet and system infrastructure functionality, information technology security, breakdown of strategic alliances, and international and political considerations, as well as those risks and uncertainties discussed in Intermap’s Annual Information Form and other securities filings. In addition, completion of the Arrangement is subject to receipt of court approvals, together with the satisfaction or waiver of certain conditions precedent to the Arrangement which are outside of the control of Intermap. While the Company makes these forward-looking statements in good faith, should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary significantly from those expected. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements, including the Arrangement, will transpire or occur, or if any of them do so, what benefits that the Company will derive therefrom. All subsequent forward-looking statements, whether written or oral, attributable to Intermap or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. The forward-looking statements contained in this news release are made as at the date of this news release and the Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements made herein, whether as a result of new information, future events or otherwise, except as may be required by applicable securities law.

About Intermap Technologies 
Intermap Technologies is a global leader in geospatial intelligence powered by proprietary 3D data and AI-driven analytics. The Company delivers actionable intelligence to government and commercial customers through a portfolio of applications, platforms and solutions that support risk management, infrastructure planning, operational readiness and mission-critical decision-making. Intermap’s proprietary 3D data foundation spans more than 300 million square kilometers across over 150 countries and powers intelligence solutions for government, insurance, aviation, telecommunications, transportation, renewable energy, agriculture, natural resources and space markets. Through advanced analytics, automated processing and enterprise-scale data delivery, Intermap helps organizations transform complex geospatial information into decision-ready intelligence. 

About CATALYST (PCI)
PCI (DBA CATALYST) is a world-leading developer of software and systems for remote sensing, imagery processing, and photogrammetry. With 45 years of experience in the geospatial industry, CATALYST is recognized globally for its excellence in providing software for accurately and rapidly processing satellite and aerial imagery, with more than 30,000 licenses in over 150 countries worldwide.

For more information, please visit www.intermap.com or contact:
Jennifer Bakken
Executive Vice President and CFO
CFO@intermap.com
+1 (303) 708-0955

Sean Peasgood
Investor Relations
Sean@SophicCapital.com
+1 (647) 260-9266

New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience

FDA removal of the prior drug exposure limit provides greater dosing flexibility in
future clinical trials

CervoMed plans to advance a 100 mg twice-daily regimen expected to achieve higher plasma trough drug concentrations than those associated with clinical activity in prior trials

BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) — CervoMed Inc. (“CervoMed” or the “Company”) (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced pharmacokinetic (PK), regulatory, and manufacturing advances that enable a higher-dose, twice-daily (BID) oral regimen of neflamapimod in future clinical trials.

The developments include a new neflamapimod 50 mg oral tablet formulation with a PK profile favorable for twice-daily dosing, the U.S. Food and Drug Administration’s (FDA) removal of the previous plasma drug exposure limit, and the implementation of a controlled manufacturing process designed to support reproducible, large-scale tablet production.

“The new 50 mg tablet addresses the formulation issue identified during the Phase 2b RewinD-LB study and we intend to move forward with it in future clinical development,” said John J. Alam, M.D., Chief Executive Officer of CervoMed. “Combined with the FDA’s removal of the prior exposure limit, the new pharmacokinetic profile enables us to advance a 100 mg twice-daily regimen that we expect will achieve substantially higher trough drug concentrations than those associated with clinical activity in previous trials, while reducing dosing frequency from three times to twice daily. These developments substantially reduce both clinical execution and manufacturing risk as we move the neflamapimod program forward.”

Supporting Data and Details

Formulation and manufacturing: New 50 mg tablet
The new 50 mg tablet contains the most stable crystalline form of neflamapimod, addressing the manufacturing variability seen with the 40 mg capsule used in the Phase 2b RewinD-LB study. This updated formulation is designed to provide a consistent drug product for future trials and, if approved, commercial supply. The new controlled manufacturing process enables reproducible, large-scale production of the tablet, thus reducing chemistry, manufacturing and controls (CMC) risk.

The new tablet was evaluated in a Phase 1 food-effect and drug-exposure study that met its primary objectives. After single-dose administration, the 50 mg tablet and the prior 40 mg capsule (previously referred to as “DP Batch B”) produced similar overall plasma drug exposure. However, the new tablet demonstrated a PK profile better suited to BID administration, with approximately 20% lower peak plasma concentration (C_max) and approximately 20% higher plasma concentration 12 hours post dose (C_trough, with BID dosing).

Regulatory: FDA removal of drug exposure limit
A 39-week dog toxicology study completed in the first half of 2026 established a no-observed-adverse-effect level (NOAEL) based on plasma drug levels, that was three-fold higher than in prior dog toxicology studies, and more than 30-fold higher than the pharmacologically and clinically active exposure range observed in previously completed clinical trials of neflamapimod in central nervous system disorders. After reviewing these data, the FDA removed the plasma drug exposure limit that had constrained neflamapimod dosing, providing CervoMed greater dosing flexibility in future clinical trials.

Dose selection: 100 mg twice daily
Based on the observed PK profile and pharmacokinetic pharmacodynamic (PK-PD) relationships across the neflamapimod clinical trials, CervoMed plans to advance a 100 mg BID regimen in future clinical trials. PK modeling indicates that the higher daily dose is expected to increase trough plasma drug concentrations by approximately 33% relative to the 40 mg three times a day (TID) regimen used in the Phase 2a clinical trial and the extension phase of the Phase 2b clinical trial in dementia with Lewy bodies (DLB).

The clinical safety and tolerability of the planned higher dose regimen are further supported by clinical data with neflamapimod administered at 80 mg BID (two 40 mg capsules), presented at the Alzheimer’s Association International Conference (AAIC) in July 2026. Compared with 80 mg BID, the planned 100 mg BID tablet regimen is expected to provide similar overall plasma drug exposure, with a higher C_trough and lower C_max.

These PK characteristics are particularly relevant to neflamapimod because previously reported PK-PD analyses indicate that clinical activity is associated with C_trough, while safety and tolerability are more closely related to C_max. The planned regimen is therefore designed to increase pharmacologically relevant trough concentrations without a commensurate increase in peak drug exposure.

About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology. In November 2025, CervoMed announced alignment with the FDA on a potential registration path for neflamapimod in DLB, and the Company is currently focused on identifying a strategic partner to advance neflamapimod into a Phase 3 trial in DLB. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.

Forward-Looking Statements
This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the Company’s need to acquire sufficient funding, including funding (through a strategic partnership or otherwise) for any Phase 3 trial in patients with DLB; the Company’s plan to focus on strategic partnering to advance neflamapimod into Phase 3 for DLB and the timing of entering into any such partnership, if at all; the therapeutic potential of neflamapimod in DLB, nfvPPA, ALS, or any other indication, including the degree of sustainability of any therapeutic effects, its potential impact on the rate of disease progression and/or clinical worsening, the optimal dosing regimen to achieve therapeutic effects, or any other treatment effects observed in any clinical trial on any clinical, biomarker, or other outcome measure, the expected pharmacokinetic profile, drug exposure, or other characteristics of the new 50 mg tablet formulation or the planned 100 mg twice-daily dosing regimen, including initial biomarker data from the Company’s Phase 2a trial in nfvPPA; the anticipated timing and achievement of clinical and development milestones, including the Company’s initiation of any Phase 3 trial in patients with DLB or the impact, if any, of the Innovation Passport Designation on any future regulatory milestone or the timing thereof; the anticipated data readouts from the Company’s Phase 2a trial in nfvPPA and the anticipated dosing of the first patient with neflamapimod in the EXPERTS-ALS trial; and any other expected or implied benefits, results, or expectations, including the extent (if any) to which neflamapimod may demonstrate efficacy or other clinical or biomarker improvements in patients with DLB or in any other indication. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be a reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company’s available cash resources, the availability of additional funds on acceptable terms or at all, and the Company’s ability to continue as a going concern; the results of the Company’s clinical trials; the Company’s ability to successfully enter into a partnership to advance neflamapimod into Phase 3 for DLB in a timely manner, on acceptable terms, or at all; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA or other regulators; the Company’s ability to maintain the intellectual property protection afforded by the Company’s patent portfolio; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (SEC) on March 13, 2026, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.

Contacts

Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431

Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902

New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience

FDA removal of the prior drug exposure limit provides greater dosing flexibility in
future clinical trials

CervoMed plans to advance a 100 mg twice-daily regimen expected to achieve higher plasma trough drug concentrations than those associated with clinical activity in prior trials

BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) — CervoMed Inc. (“CervoMed” or the “Company”) (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced pharmacokinetic (PK), regulatory, and manufacturing advances that enable a higher-dose, twice-daily (BID) oral regimen of neflamapimod in future clinical trials.

The developments include a new neflamapimod 50 mg oral tablet formulation with a PK profile favorable for twice-daily dosing, the U.S. Food and Drug Administration’s (FDA) removal of the previous plasma drug exposure limit, and the implementation of a controlled manufacturing process designed to support reproducible, large-scale tablet production.

“The new 50 mg tablet addresses the formulation issue identified during the Phase 2b RewinD-LB study and we intend to move forward with it in future clinical development,” said John J. Alam, M.D., Chief Executive Officer of CervoMed. “Combined with the FDA’s removal of the prior exposure limit, the new pharmacokinetic profile enables us to advance a 100 mg twice-daily regimen that we expect will achieve substantially higher trough drug concentrations than those associated with clinical activity in previous trials, while reducing dosing frequency from three times to twice daily. These developments substantially reduce both clinical execution and manufacturing risk as we move the neflamapimod program forward.”

Supporting Data and Details

Formulation and manufacturing: New 50 mg tablet
The new 50 mg tablet contains the most stable crystalline form of neflamapimod, addressing the manufacturing variability seen with the 40 mg capsule used in the Phase 2b RewinD-LB study. This updated formulation is designed to provide a consistent drug product for future trials and, if approved, commercial supply. The new controlled manufacturing process enables reproducible, large-scale production of the tablet, thus reducing chemistry, manufacturing and controls (CMC) risk.

The new tablet was evaluated in a Phase 1 food-effect and drug-exposure study that met its primary objectives. After single-dose administration, the 50 mg tablet and the prior 40 mg capsule (previously referred to as “DP Batch B”) produced similar overall plasma drug exposure. However, the new tablet demonstrated a PK profile better suited to BID administration, with approximately 20% lower peak plasma concentration (C_max) and approximately 20% higher plasma concentration 12 hours post dose (C_trough, with BID dosing).

Regulatory: FDA removal of drug exposure limit
A 39-week dog toxicology study completed in the first half of 2026 established a no-observed-adverse-effect level (NOAEL) based on plasma drug levels, that was three-fold higher than in prior dog toxicology studies, and more than 30-fold higher than the pharmacologically and clinically active exposure range observed in previously completed clinical trials of neflamapimod in central nervous system disorders. After reviewing these data, the FDA removed the plasma drug exposure limit that had constrained neflamapimod dosing, providing CervoMed greater dosing flexibility in future clinical trials.

Dose selection: 100 mg twice daily
Based on the observed PK profile and pharmacokinetic pharmacodynamic (PK-PD) relationships across the neflamapimod clinical trials, CervoMed plans to advance a 100 mg BID regimen in future clinical trials. PK modeling indicates that the higher daily dose is expected to increase trough plasma drug concentrations by approximately 33% relative to the 40 mg three times a day (TID) regimen used in the Phase 2a clinical trial and the extension phase of the Phase 2b clinical trial in dementia with Lewy bodies (DLB).

The clinical safety and tolerability of the planned higher dose regimen are further supported by clinical data with neflamapimod administered at 80 mg BID (two 40 mg capsules), presented at the Alzheimer’s Association International Conference (AAIC) in July 2026. Compared with 80 mg BID, the planned 100 mg BID tablet regimen is expected to provide similar overall plasma drug exposure, with a higher C_trough and lower C_max.

These PK characteristics are particularly relevant to neflamapimod because previously reported PK-PD analyses indicate that clinical activity is associated with C_trough, while safety and tolerability are more closely related to C_max. The planned regimen is therefore designed to increase pharmacologically relevant trough concentrations without a commensurate increase in peak drug exposure.

About CervoMed
CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology. In November 2025, CervoMed announced alignment with the FDA on a potential registration path for neflamapimod in DLB, and the Company is currently focused on identifying a strategic partner to advance neflamapimod into a Phase 3 trial in DLB. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.

Forward-Looking Statements
This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to: the Company’s need to acquire sufficient funding, including funding (through a strategic partnership or otherwise) for any Phase 3 trial in patients with DLB; the Company’s plan to focus on strategic partnering to advance neflamapimod into Phase 3 for DLB and the timing of entering into any such partnership, if at all; the therapeutic potential of neflamapimod in DLB, nfvPPA, ALS, or any other indication, including the degree of sustainability of any therapeutic effects, its potential impact on the rate of disease progression and/or clinical worsening, the optimal dosing regimen to achieve therapeutic effects, or any other treatment effects observed in any clinical trial on any clinical, biomarker, or other outcome measure, the expected pharmacokinetic profile, drug exposure, or other characteristics of the new 50 mg tablet formulation or the planned 100 mg twice-daily dosing regimen, including initial biomarker data from the Company’s Phase 2a trial in nfvPPA; the anticipated timing and achievement of clinical and development milestones, including the Company’s initiation of any Phase 3 trial in patients with DLB or the impact, if any, of the Innovation Passport Designation on any future regulatory milestone or the timing thereof; the anticipated data readouts from the Company’s Phase 2a trial in nfvPPA and the anticipated dosing of the first patient with neflamapimod in the EXPERTS-ALS trial; and any other expected or implied benefits, results, or expectations, including the extent (if any) to which neflamapimod may demonstrate efficacy or other clinical or biomarker improvements in patients with DLB or in any other indication. Terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “aims,” “seeks,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately,” “potential,” “target,” “project,” “contemplate,” “predict,” “forecast,” “continue,” or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be a reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company’s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company’s available cash resources, the availability of additional funds on acceptable terms or at all, and the Company’s ability to continue as a going concern; the results of the Company’s clinical trials; the Company’s ability to successfully enter into a partnership to advance neflamapimod into Phase 3 for DLB in a timely manner, on acceptable terms, or at all; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the FDA or other regulators; the Company’s ability to maintain the intellectual property protection afforded by the Company’s patent portfolio; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 filed with the U.S. Securities and Exchange Commission (SEC) on March 13, 2026, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.

Contacts

Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431

Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902